¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11
±³À°ÀÏÀÚ : 2024-05-11
±³À°Àå¼Ò : ´õÄÉÀÌÈ£ÅÚ ¼­¿ï ±Ý°­È¦

±³À°ÁÖÁ¦ : The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium

ÁÖÃÖ±â°ü : ´ëÇÑÀü¸³¼±ÇÐȸ
´ã´çÀÚ : ±è¹ÎÈñ
¿¬¶ôó : 010-8584-0193  

À̸ÞÀÏ : gaonpco@gaonpco.com

±³À°Á¾·ù : ºñ´¢ÀÇÇаú, ÀÇÇб³À°

Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 1Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 30ºÐ

¼¼ºÎ¼ö°­·á : 30,000¿ø  

ºñ°í »çÀüµî·Ï Àü¹®ÀÇ 2¸¸¿øÀü°øÀÇ 1¸¸¿ø ÇöÀåµî·ÏÀü¹®ÀÇ 3¸¸¿øÀü°øÀÇ 2¸¸¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 13:00~13:15 Locally advanced cancer (very high-risk or N1) in the PSMA era Á¶Á¤±â(ÇѾçÀÇ´ë)

Åä·Ð 05¿ù 11ÀÏ ±Ý°­È¦ 13:15~13:45 Panel discussion ±èÅûó(°í½ÅÀÇ´ë)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 13:45~14:00 Tactics of ADT administration - continous vs. intermittent ÀÌÇйÎ(¼­¿ïÀÇ´ë)

Åä·Ð 05¿ù 11ÀÏ ±Ý°­È¦ 14:00~14:30 Panel discussion ±èº´ÈÆ(°è¸íÀÇ´ë)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 14:50~15:05 Treatment choice following doublet/triplet therapy for mHSPC ¹ÚÁ¾¿í(¿øÀڷº´¿ø)

Åä·Ð 05¿ù 11ÀÏ ±Ý°­È¦ 15:05~15:35 Panel discussion Á¶¹®±â(¿øÀڷº´)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 15:35~15:50 The positioning of olaparib/abiraterone within mCRPC sequencing ÇÑÇöÈ£(¿¬¼¼ÀÇ´ë)

Åä·Ð 05¿ù 11ÀÏ ±Ý°­È¦ 15:50~16:20 Panel discussion Á¤Àç½Â(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 16:20~16:35 Apalutamide rash prevalence study: Updated results ±è¿øÅÂ(ÃæºÏÀÇ´ë)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 16:35~16:50 PSMA theranostics for prostate cancer ¼­¹Î¼®(¼­¿ïÀÇ´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¸¸¼ºÆó¼â °ü»óµ¿¸Æ ÁßÀç½Ã¼ú¿¬±¸È¸ The 23rd K-CTO(Korean Chronic Total Occlusion Club) Live Demonstration : 2024-05-11
´ÙÀ½±Û 2024 ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2024-05-11
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
317 ´ëÀü 2018 ´ëÇÑ¿Ü°ú¼ú±â¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö ¹× Æ©ÅÍ ¿öÅ©¼ó : 2018-08-25 0 419 2018-08-08
316 Ãæ³² Àü³²´ëÇб³º´¿ø 2018 Á¦ 20Â÷ ºû°íÀ»½½°üÀý¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2018-08-25 0 743 2018-08-08
315 ´ëÀü ´ëÇѳëÀÎÁ¤½ÅÀÇÇÐȸ Á¦10ȸ Ä¡¸ÅÁø·áÀÇ»ç Àü¹®È­±³À° (part3, 1ÀÏÂ÷) : 2018-08-25 0 773 2018-08-08
314 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø 2018 Yunsei Nuclear Medicien Review course : 2018-08-25 0 533 2018-08-08
313 ¼­¿ï °­µ¿°æÈñ´ëÇб³º´¿ø 2018 °­µ¿°æÈñ´ëÇб³ Á¤Çü¿Ü°ú ½ÉÆ÷Áö¿ò : 2018-08-25 0 1,764 2018-08-08
312 ±¤ÁÖ Àü³²´ëÇб³º´¿ø 2018³â Á¦4ȸ ½Å°æ¿Ü°ú °³¿øÀÇ ¿¬¼ö°­Á : 2018-08-25 0 719 2018-08-08
311 ¼­¿ï 2018³âµµ ´ëÇѺ´¸®ÇÐȸ °øÅ뿪·®±³À° : 2018-08-25 0 652 2018-08-08
310 ÀÎõ ´ëÇѼҾƽÉÀåÇÐȸ Á¦ 21ȸ Update symposium of pediatric cardiology and cardiac surgery : 2018-08-25 0 479 2018-08-08
309 ¼­¿ï °Ç±¹´ëÇб³ÃæÁÖº´¿ø ´ç´¢º´, Àν¶¸°ÆßÇÁ ¿öÅ©¼¥ : 2018-08-25 0 1,033 2018-08-08
308 ±¤ÁÖ Á¶¼±´ëÇб³º´¿ø 2018 È£³²Ç×¹®Áúȯ ¿¬±¸È¸ : 2018-08-25 0 1,742 2018-08-08
307 ¼­¿ï ´ëÇѼҾƳ»ºÐºñÇÐȸ ºñ¸¸¿¬±¸Áý´ãȸ 2018³â 3Â÷ : 2018-08-23 0 371 2018-08-08
306 ºÎ»ê ºÎ»ê½Ã°³¿ø³»°úÀÇ»çȸ ¿¬¼ö°­Á : 2018-08-21 0 457 2018-08-08
305 Á¦ÁÖ Á¦ÁÖ³»ºÐºñÇÐȸ Á¦ 41Â÷ ¿¬¼ö°­Á : 2018-08-20 0 536 2018-08-08
304 ¼­¿ï ´ëÇѳ»°úÇÐȸ Á¦12Â÷ ÁöµµÀü¹®ÀÇ ±³À° : 2018-08-20 0 1,757 2018-08-08
303 ¼­¿ï Á¦42ȸ 2018³â ´ëÇÑÀϹݰúÀÇ»çȸ ÇÏ°è ¿¬¼ö°­Á : 2018-08-19 0 494 2018-08-08
1391 | 1392 | 1393 | 1394 | 1395 | 1396 | 1397 | 1398 | 1399 | 1400
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷